Targeting PCSK9: The Journey of VXX-401, a Promising New Therapy for Hypercholesterolemia, from Lab to Pilot Production
Time: 11:15 am
day: Day One
Details:
- Formulation Innovation: Explore a case study into the formulation strategies employed by Vaxxinity and Pace® Life Sciences to develop VXX-401, a synthetic peptide vaccine currently in Phase I clinical studies
- Learn about the advantages of particulate suspensions
- Challenges in scaling from the research lab to pilot manufacturing
- Aseptic formulation and filling: benefit from the shared experiences of Vaxxinity and Pace Life Sciences, gaining valuable insights into the collaborative dynamics that drive successful drug development projects
